Monte Rosa Therapeutics (GLUE) FCF Margin (2024 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly FCF Margin of 932.67% for Q1 2026, down 87875.0% year-over-year from N/an in Q1 2025, and up 39.29% quarter-over-quarter from 1536.28% in Q4 2025.
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) FCF Margin (2024 - 2026) Analysis & Trends
Monte Rosa Therapeutics' FCF Margin history runs 3 years deep, the most recent figure standing at 932.67% for Q1 2026.
- In Q1 2026, FCF Margin fell 87875.0% year-over-year to 932.67%; the TTM figure through Mar 2026 stood at 401.3% (down 42343.0% YoY), while the FY2025 annual figure was 18.55%, down 7402.0% from the prior year.
- FCF Margin for Q1 2026 stood at 932.67%, up from 1536.28% in the prior quarter.
- The five-year high for FCF Margin was 218.77% in Q4 2024, with the low at 3679.32% in Q1 2024.
- The 3-year median for FCF Margin is 232.13% (2024), against an average of 757.4%.
- Peak annual rise in FCF Margin reached 362540 bps in 2025, while the deepest fall reached 175505 bps in 2025.
- Monte Rosa Therapeutics' FCF Margin stood at 218.77% in 2024, then slumped by 802 bps to 1536.28% in 2025, then soared by 39 bps to 932.67% in 2026.
- Business Quant data shows GLUE's FCF Margin at 932.67% in Q1 2026, 1536.28% in Q4 2025, and 68.85% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Monte Rosa Therapeutics | 1.40 Bn | 771.57 Mn | - | -534.89% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -534.89% |
| Mar 31, 2026 | -952.61% |
| Dec 31, 2025 | -1,574.29% |
| Sep 30, 2025 | 781.46% |
| Jun 30, 2025 | -25.97% |
| Mar 31, 2025 | -55.43% |
| Dec 31, 2024 | 212.28% |
| Sep 30, 2024 | -232.13% |
| Jun 30, 2024 | -634.48% |
| Mar 31, 2024 | -3,717.01% |